MedTrace Logo

Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis

NCT01442779 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-04-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the possible efficacy of low dose, orally administered interferon alpha in subjects with Idiopathic Pulmonary Fibrosis (IPF).

Conditions

Interventions

DRUG

Interferon alpha oral lozenge

dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year

Sponsors & Collaborators

  • Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

    collaborator INDUSTRY

  • Texas Tech University Health Sciences Center

    lead OTHER

Principal Investigators

  • Cynthia Jumper, MD · Texas Tech University Health Sciences Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Primary Completion
2007-05-31
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01442779 on ClinicalTrials.gov